Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.
von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.
Pasi
K J
KJ
Department of Haematology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK. k.j.pasi@qmul.ac.uk
Collins
P W
PW
Keeling
D M
DM
Brown
S A
SA
Cumming
A M
AM
Dolan
G C
GC
Hay
C R M
CR
Hill
F G H
FG
Laffan
M
M
Peake
I R
IR
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D016913:Blood Component Transfusion; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D014842:von Willebrand Diseases / Q000150:complications / Q000628:therapy*
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D003894:Deamino Arginine Vasopressin